Entourage Health Corp. (ENTG.V)
CAD 0.01
(0.0%)
CAD 0.01
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -21.39 Million CAD | 58.48% |
| 2022 | -99.83 Million CAD | -59.19% |
| 2021 | -61.29 Million CAD | 35.61% |
| 2020 | -81.54 Million CAD | -635.8% |
| 2019 | -8.87 Million CAD | 33.65% |
| 2018 | -348.66 Thousand CAD | -36.65% |
| 2017 | -6.78 Million CAD | -6794.0% |
| 2016 | -98.4 Thousand CAD | -200.2% |
| 2015 | -1.75 Million CAD | 74.94% |
| 2014 | -3.08 Million CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -3.38 Million CAD | -1076.02% |
| 2024 Q1 | 510.3 Thousand CAD | 103.32% |
| 2023 FY | - CAD | 58.48% |
| 2023 Q1 | -3.91 Million CAD | 81.4% |
| 2023 Q4 | -8.57 Million CAD | -156.77% |
| 2023 Q2 | -2.47 Million CAD | 36.74% |
| 2023 Q3 | -3.33 Million CAD | -34.77% |
| 2022 Q2 | -10.29 Million CAD | -198.92% |
| 2022 Q3 | -11.59 Million CAD | -12.6% |
| 2022 FY | - CAD | -59.19% |
| 2022 Q1 | -3.44 Million CAD | 30.75% |
| 2022 Q4 | -21.05 Million CAD | -81.61% |
| 2021 FY | - CAD | 35.61% |
| 2021 Q3 | -14.16 Million CAD | -109.83% |
| 2021 Q4 | -4.97 Million CAD | 64.88% |
| 2021 Q2 | -6.75 Million CAD | -107.52% |
| 2021 Q1 | -3.25 Million CAD | 92.03% |
| 2020 Q3 | 10.22 Million CAD | 240.58% |
| 2020 Q4 | -40.81 Million CAD | -499.08% |
| 2020 Q1 | -7.39 Million CAD | -58.61% |
| 2020 Q2 | -7.27 Million CAD | 1.66% |
| 2020 FY | - CAD | -635.8% |
| 2019 Q3 | -12.72 Million CAD | -194.01% |
| 2019 Q1 | -2.29 Million CAD | 70.48% |
| 2019 Q2 | 13.54 Million CAD | 689.2% |
| 2019 Q4 | -4.66 Million CAD | 63.36% |
| 2019 FY | - CAD | 33.65% |
| 2018 Q2 | -1.14 Million CAD | -71.34% |
| 2018 FY | - CAD | -36.65% |
| 2018 Q4 | -7.78 Million CAD | -1775.24% |
| 2018 Q3 | 464.73 Thousand CAD | 140.66% |
| 2018 Q1 | -667.08 Thousand CAD | 61.56% |
| 2017 Q2 | -4.27 Million CAD | -1352.76% |
| 2017 FY | - CAD | -6794.0% |
| 2017 Q4 | -1.73 Million CAD | -261.57% |
| 2017 Q1 | -294.2 Thousand CAD | -410.94% |
| 2017 Q3 | -479.99 Thousand CAD | 88.77% |
| 2016 Q1 | -6081.00 CAD | 72.98% |
| 2016 Q4 | -57.58 Thousand CAD | -444.66% |
| 2016 Q3 | -10.57 Thousand CAD | 56.26% |
| 2016 Q2 | -24.16 Thousand CAD | -297.43% |
| 2016 FY | - CAD | -200.2% |
| 2015 Q3 | -616.00 CAD | 81.9% |
| 2015 FY | - CAD | 74.94% |
| 2015 Q2 | -3403.00 CAD | 45.56% |
| 2015 Q1 | -6251.00 CAD | 94.24% |
| 2015 Q4 | -22.5 Thousand CAD | -3554.06% |
| 2014 Q3 | -22.24 Thousand CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| 2014 Q4 | -108.57 Thousand CAD | -388.09% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Aequus Pharmaceuticals Inc. | -2.68 Million CAD | -697.981% |
| CanadaBis Capital Inc. | 5.67 Million CAD | 476.845% |
| Decibel Cannabis Company Inc. | 5.67 Million CAD | 476.772% |
| Delivra Health Brands Inc. | 2.35 Million CAD | 1008.958% |
| Lifeist Wellness Inc. | -12.76 Million CAD | -67.559% |
| Cannara Biotech Inc. | 17.18 Million CAD | 224.493% |
| Medicure Inc. | 1.27 Million CAD | 1780.823% |
| PharmaCielo Ltd. | -12.01 Million CAD | -78.031% |
| Rubicon Organics Inc. | 1.94 Million CAD | 1198.402% |
| BioSyent Inc. | 9.05 Million CAD | 336.231% |
| Voyageur Pharmaceuticals Ltd. | -1.22 Million CAD | -1652.475% |